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Toll-like receptor 8 (TLR-8) plays a role in the pathogenesis of autoimmune disorders
and associated gastrointestinal symptoms that reduce quality of life of patients. Dietary
interventions are becoming more accepted as mean to manage onset, progression, and
treatment of a broad spectrum of inflammatory conditions. In this study, we assessed
the impact of N-glycans derived from bovine lactoferrin (bLF) on the inhibition of TLR-8
activation. We investigated the effects of N-glycans in their native form, as well as in its
partially demannosylated and partially desialylated form, on HEK293 cells expressing
TLR-8, and in human monocyte-derived dendritic cells (MoDCs). We found that in
HEK293 cells, N-glycans strongly inhibited the ssRNA40 induced TLR-8 activation but
to a lesser extent the R848 induced TLR-8 activation. The impact was compared with
a pharmaceutical agent, i.e., chloroquine (CQN), that is clinically applied to antagonize
endosomal TLR- activation. Inhibitory effects of the N-glycans were not influenced by
the partially demannosylated or partially desialylated N-glycans. As the difference in
charge of the N-glycans did not influence the inhibition capacity of TLR-8, it is possible
that the inhibition mediated by the N-glycans is a result of a direct interaction with the
receptor rather than a result of pH changes in the endosome. The inhibition of TLR-
8 in MoDCs resulted in a significant decrease of IL-6 when cells were treated with
the unmodified (0.5-fold, p < 0.0001), partially demannosylated (0.3-fold, p < 0.0001)
and partially desialylated (0.4-fold, p < 0.0001) N-glycans. Furthermore, the partially
demannosylated and partially desialylated N-glycans showed stronger inhibition of IL-
6 production compared with the native N-glycans. This provides evidence that glycan
composition plays a role in the immunomodulatory activity of the isolated N-glycans
from bLF on MoDCs. Compared to CQN, the N-glycans are specific inhibitors of TLR-
8 activation and of IL-6 production in MoDCs. Our findings demonstrate that isolated
N-glycans from bLF have attenuating effects on TLR-8 induced immune activation in
HEK293 cells and human MoDCs. The inhibitory capacity of N-glycans isolated from
bLF onTLR-8 activation may become a food-based strategy to manage autoimmune,
infections or other inflammatory disorders.
Keywords: N-glycosylation, bovine lactoferrin, inhibition, TLR-8, immunomodulation, autoimmune disorders
Abbreviations: bLF, Bovine lactoferrin; Mo, Monocytes; MoDCs, Monocyte-derived dendritic cells; PBMCs, Peripheral
blood mononuclear cells; TLR-8, Toll-like receptor 8.
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INTRODUCTION
Bovine lactoferrin (bLF) is a milk derived glycosylated protein
with confirmed anti-viral (1), anti-bacterial, anti-fungal, anti-
oxidant (2), and immunomodulating properties (3). It is
present in bovine colostrum and mature milk at concentration
of 1.5–5 mg/mL and 1.5–3 mg/mL, respectively (4). The
human equivalent is present in at least ten times higher
concentrations in breast milk (5). When mother milk is not
an option or insufficiently produced, infants are receiving bLF
via infant formula (3). Besides its use in infant formula, bLF
is widely used as a functional food product and has many
biopharmaceutical applications (6). Several studies have been
dedicated to the characterization of the structure of bLF, mostly
to the determination of its amino acid sequence (7) and N-glycan
composition (8). However, the relationship between its structural
make-up and biological functionality has been less explored. So
far, most research has been dedicated to the activity against
Gram-positive and Gram-negative bacteria of LF and the role of
the protein core in such bactericidal properties (9, 10).
The impact of N-glycosylation of bLF, i.e., the attachment
of glycan moieties to specific sites of the protein, on its
biological activity has not been studied in much detail. Although
the structural homology of bLF compared with human LF
(hLF) is 77% (11), the glycosylation pattern of bLF, differs
significantly from the human counterpart (7). While hLF
has 3 N-glycosylation sites, bLF has 5 (12). The N-glycans
of bLF consist of units of N-acetyl-galactosamine (GalNAc),
N-acetyl-glucosamine (GlcNAc), galactose, mannose, fucose, and
sialic acid [N-acetyl-neuraminic acid (Neu5Ac) and N-glycolyl-
neuraminic acid (Neu5Gc)]. Neu5Gc is only present on bLF
and not present on human LF (13). N-glycosylation determines
many characteristics of the bLF, such as the conformation,
folding, solubility, and resistance to protein proteolysis (14) and
its iron-binding capacity (15). The heterogeneity in the glycan
chain monosaccharide composition of bLF is considered to be
relevant for the broad spectrum of biological effects of human
and bLF (13).
Chromatographic analysis of whey proteins in bovine milk
has shown pertinent differences in N-glycosylation composition
between human and bLF (16). Human LF consists of 6% oligo-
mannose type glycans and 52% of complex/hybrid type glycans,
of which 48% of the glycans are sialylated and 88% fucosylated
(16). In contrast, bLF consists of 65% oligo-mannose and 4%
complex/hybrid type glycans. Of these glycans 31% is sialylated
and 9% fucosylated (16). The glycosylation pattern of bLF is
known to change during lactation as a mechanism to respond
to a broader spectrum of pathogens (17). Most of these studies
were performed with mixtures of bLF and not with the N-glycans
alone as it is cumbersome to obtain large enough samples
to perform functional studies. New analytical techniques have
changed this (18) and led to the characterization of structural
components responsible for the anti-oxidant, iron binding (19)
and immunomodulatory capacity of bLF (20).
The immunomodulatory capacity is another important
biological activity of bLF (21). The oral administration of bLF has
been shown to attenuate both, human and non-human immune
inflammatory responses (22). This modulation is attributed to the
ability of bLF to bind to lipopolysaccharides (LPS) and activate
TLR-4 (23). LF has also been reported to enhance the activation
of T-cells through modulation of dendritic cell responses (24).
Most recently, it has been shown by us that the glycosylation
pattern of bLF determines the TLR modulating capacity of bLF.
A property of bLFN-glycans is that they antagonize the activation
of TLR-8 (20).
Toll-like receptor 8 recognizes structural patterns of viral and
bacterial ssRNA and it is expressed in lymphocytes, monocytes
(Mo), and intestinal epithelial cells (IEC) (25). Additionally, TLR-
8 can recognize self-RNA (26) and a small synthetic antiviral
imidazoquinoline called resiquimod (R848). The dysregulation
or overexpression of TLR-8 has been found to contribute to
the pathogenesis and progression of autoimmune disorders,
such as rheumatoid arthritis (27), systemic sclerosis (28), and
inflammatory bowel disease (29). Inhibition of endosomal TLRs,
such as TLR-8 has great therapeutic potential for the treatment
of autoimmune diseases (30–32) as shown for the TLR7/8/9
antagonist chloroquine (CQN). Therefore, the inhibition of TLR-
8 activation might be instrumental for the management of many
inflammatory conditions (32, 33).
In experimental settings, the TLR-8 activation by RNA
is mimicked with compounds such as HIV-derived ssRNA40
and R848. Although both compounds activate TLR-8 via the
adaptor molecule Myd88, it has been shown that CQN inhibits
ssRNA40 induced activation of TLR-8 but only to a minor
extent antagonizes R848 induced TLR-8 activation (34). These
differences in efficacy of TLR-8 inhibition by CQN have been
attributed to different mechanisms of inhibition (35). Endosomal
TLRs require the acidification of the endosome for their
activation. By preventing this process, CQN inhibits TLR-8
signaling (36). The other mechanism involves two possibilities:
either the direct interaction of CQN with TLRs ligands or the
disruption of the configuration changes of the TLR-8 dimer
structure required for activation (37).
In order to gain more insight in the interactions of the isolated
N-glycans from bLF and its partially demannosylated and
partially desialylated counterparts, we compared the inhibitory
effect of N-glycans on the ssRNA40 and R848 induced activation
of TLR-8 in HEK293 cells. In addition, we investigated
whether these N-glycans were able to exert different inhibitory
effects on the activation of TLR-8 and the production of
cytokines in MoDCs.
MATERIALS AND METHODS
Preparation of N-Glycan Fractions
Bovine lactoferrin was provided by FrieslandCampina Domo
(Amersfoort, Netherlands). PNGase F (Flavobacterium
meningosepticum) was from New England Biolabs (Ipswich,
United Kingdom). Bio-Beads SM-2 were purchased from
Bio-Rad Laboratories (Veenendaal, Netherlands). Solid phase
extraction (SPE) of the large-scale PNGase F digests was
performed on, prepacked C18 (CEC18, 200 mg;3mL, Screening
Devices, Amersfoort, Netherlands) and graphitized carbon
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FIGURE 1 | Schematic representation of the preparation of the N-glycan fractions.
SPE cartridges (Extract-clean carbograph, 150 mg;4mL, Grace,
Columbia, United States). In order to alter the content of
mannose and sialic acid on the glycan chains of bLF, the native
protein was incubated with α-mannosidase and sialidase as
reported previously (20).
Purified glycans were obtained using the method described
by Valk-Weeber et al. (18). One gram of bLF was dissolved at
a concentration of 7.5 mg/mL in 100 mM sodium phosphate
buffer (pH 7.5). SDS was added at a 1:1 w/w protein: SDS ratio
and β-mercaptoethanol (Sigma) was added to a concentration
of 1% v/v. The protein was denatured by heating at 85◦C
for 30 min. Denatured protein was alkylated by addition of
iodoacetamide (Sigma) to a concentration of 20 mM (55◦C;
30 min). This step was performed in the dark because of
instability of iodoacetamide in light. Nonidet P-40 substitute (NP-
40, Sigma) was added at a final concentration of 1% v/v. PNGase
F was added at a concentration of 50 U/mg glycoprotein and the
solution incubated overnight at 37◦C with continuous agitation.
Detergents were removed with Bio-Beads SM-2 (Bio-Rad) using
1 g of beads: 10 mg of digested protein. Protein was removed
by 30 kDa centrifugal MWCO filters (Amicon Ultra, Merck
Millipore, Tullagreen, Cork, Ireland). The partially purified digest
was further purified by C18 and graphitized carbon SPE. Aqueous
glycan samples were loaded onto conditioned C18 material
and the flow through, containing glycans, was collected and
loaded onto the graphitized carbon. The graphitized carbon was
washed with MilliQ water to remove salts and finally the glycans
were eluted with 25% acetonitrile containing 0.1% TFA. Elution
fractions were neutralized with 2% ammonia, the acetonitrile
evaporated under N2 and lyophilized. Residual detergent traces
were removed by washing the lyophilized N-glycans with 5 mL
100% ice cold (−20◦C) acetone. Purity of the resulting glycan
products was determined by monosaccharide analysis and 1D 1H
NMR spectroscopy as described (18). A schematic overview of
the enzymatic treatment is presented in Figure 1.
Cell Culture of HEK293-TLR-8 Cell Line
HEK-BlueTM hTLR-8 reporter cell lines and reagents, such
as selection media Quanti-BlueTM reagent, and the agonists
single-stranded GU-rich oligonucleotide complexed with LyoVec
(ssRNA40/LyoVecTM) and R848 (resiquimod), were purchased
from InvivoGen (Toulouse, France). This cell line carries a
construct for SEAP coupled to the NF-κB/AP-1 promoter. The
HEK-BlueTM-hTLR8 cell line was maintained in DMEM (Life
Technologies Europe B.V) containing 10% heat inactivated
fetal bovine serum (FBS), L-glutamine (2.0 mM-Sigma-Aldrich
Chemie B.V), glucose (4.5g/L Sigma-Aldrich Chemie B.V),
penicillin-streptomycin (50 U/mL–50 µg/mL Sigma-Aldrich
Chemie B.V), and normocyn (100 µg/mL Sigma-Aldrich Chemie
B.V). HEK-BlueTM hTLR8 cells were grown to approximately
80% of confluence. After culturing for 3 passages, all reporter
cell lines were maintained on selection media according to the
manufacturer’s protocol.
TLR Activation and Inhibition Assays in
Reporter Cell Line Experiments
HEK-BlueTM hTLR8 cell lines were detached from the bottom
flask after which the cells were centrifuged and re-suspended
according to manufacturer’s protocol. Later the cells were seeded
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at 2.2 × 105 cells/mL in 96 well plates at 100 µL per well.
Inhibition of TLR-8 activation was studied by comparing the
NF-κB release of TLRs agonists (ssRNA40, R848) with the
NF-κB release of cells co-incubated with TLR agonist and
inhibitors. TLR-8 inhibitor, CQN, was acquired from Sigma-
Aldrich Chemie B.V. The native, partially demannosylated
and partially desialylated N-glycans were prepared as reported
previously (20). The cells were incubated for 1 h with 10 µL
of inhibitor (CQN or N-glycans fractions); afterward 10 µL of
agonist was added. All compounds were dissolved in culture
medium. The plates were incubated for 24 h at 37◦C and 5%
CO2. After this period, 20 µL of supernatant were mixed with
180 µL of Quanti-BlueTM in flat bottom 96 well plates. The plate
was incubated for 1 h at 37◦C and 5% CO2. After incubation,
the activity of SEAP turns Quanti-BlueTM substrate to blue color.
The NF-kB release was quantified at 650 nm in a Benchmark
Plus Microplate Reader using Microplate Manager 5.2.1 version
for data acquisition. The assays were performed with 4 technical
repeats and each experiment was at least repeated 4 times.




Blood sampling of human volunteers was conducted within the
University Medical Center Groningen (UMCG), Netherlands.
Written informed consent was obtained and data was analyzed
and presented anonymously. This research and consent
procedure have been approved by the Ethical Review Board
of the UMCG, as documented in the approved application
“2007/255.”
Human Peripheral Blood Mononuclear Cells (PBMCs)
Isolation and Monocyte (Mo) Purification
Human PBMCS were obtained using density gradient
centrifugation. Whole blood was collected in EDTA tubes. The
blood was diluted 1:1 with PBS free of calcium and magnesium.
PBMCs were obtained by a Ficoll density gradient isolation
(Lymphoprep, Stemcell Technologies, Cologne, Germany). From
the freshly isolated PBMCs, CD14+ Mo were isolated using
the EasySep Human Monocyte Isolation Kit (negative selection
kit, Stemcell Technologies, Cologne, Germany) according to
manufacturer’s instructions.
MoDCs Differentiation and Maturation
Purified Mo were seeded in IMDM medium supplemented with
1% FBS and 1000 ng/mL of granulocyte-macrophage colony
stimulating factor (GM-CSF) and 500U/mL of interleukin-4 (IL-
4) (ImmunoTools, Germany) for a total of 6 days in 24-well
culture plates at a density of 5× 105 cells/mL (38).
Inhibition of TLR-8 Activation in MoDCs
Experiment
Monocyte-derived dendritic cells were cultured in 96-well plates
at a density of 50,000 cells per well. Non-treated cells served as
negative control. To inhibit TLR-8 activation, CQN was used at a
concentration of 10 µg/mL. The native, partially demannosylated
and partially desialylated N-glycans isolated from bLF were tested
to examine their ability to inhibit TLR-8 activation. Cells were
either incubated for 1 h with CQN or with the N-glycan samples.
After this time, cells were co-incubated with the agonist ssRNA40
for 24 h. The supernatant was collected for further analysis.
Real-Time PCR Measurement of TLR8
mRNA Expression
Total RNA was isolated and purified from Mo and MoDCs
with TRIzol reagent (Invitrogen). Superscript II reverse
transcription kit (Invitrogen) was used. The levels of TLR-8
isoform Hs00607866_mH probe (Thermo Fisher Scientific) were
measured using real-time PCR Taqman assay. Samples were run
in triplicate. The relative expression of the TLR-8 isoform was
normalized to the housekeeper GAPDH and calculated with the
2−11Ct method (39).
Cytokine Detection by Enzyme-Linked
Immunosorbent Assay (ELISA)
The culture supernatants of the MoDCs were removed after
24 h. The production of IL-6, IL-10 and TNF-α was measured
in 96-well microtiter plates according to the manufacturer’s
instructions (R&D Systems, DuoSet). Standard curves and
sample concentrations were calculated based on the mean of
triplicates for each sample.
Statistical Analysis
Statistical analysis was performed using Graphpad 7. Normal
distribution of the data sets was tested using Shapiro-Wilk
normality test. Data was normally distributed and expressed as
mean± SEM. Statistical comparisons were performed using one-
way ANOVA followed by post hoc Tukey’s multiple comparison
test to show individual differences. A p-value < 0.05 was
considered significantly different. Statistical differences in the
release of NF-κB in the HEK293 cells expressing hTLR-8 were
evaluated using paired t-test. A p-value < 0.05 was considered
significantly different.
RESULTS
Structural Characterization of Isolated
Glycans From bLF
To obtain N-glycans from bLF in milligram amounts, which is
needed to perform functional studies, a large-scale protocol for
the purification and characterization of isolated N-glycans from
bLF was developed (18). Prior to glycan release, the N-glycans
were enzymatically treated to reduce the content of mannose and
sialic acid. These modifications were done to study the impact of
such reductions on the inhibition of TLR-8 activation in reporter
cell lines (HEK293 hTLR-8) and in MoDCs.
As indicated in Figure 2A, the glycan composition of native
N-glycans on bLF consists mainly of oligomannoses Man-5 to
Man-9 and a small number of sialylated biantennary glycans.
The mannosidase treatment (Figure 2B), reduced the mannose
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FIGURE 2 | Glycoprofile of the N-glycans isolated from bLF. (A) Native isolated N-glycans, (B) partially demannosylated N-glycans, and (C) partially desialylated
N-glycans.
content with 11%, based on the monosaccharide analysis (data
not shown). However, this overall reduction is not the only
change induced by the mannosidase treatment, as the pattern
of the oligomannose glycans was drastically altered. While Man-
3 to Man-7 structures were still present, Man-8 and Man-9
had virtually disappeared. The characterization of the N-glycans
treated with sialidase is presented in Figure 1C. Based on the
monosaccharide analysis, sialic acid content was reduced by 94%.
This is also reflected by the absence of sialylated structures and
the increase of desialylated variants (Figure 2C).
Differential TLR-8 Inhibition by
N-Glycans Isolated From bLF
We have previously found that TLR-8 is inhibited by the
N-glycans isolated from bLF (20). Inhibition of endosomal
TLR-8 signaling is a possible approach to modulate the
immune response in autoimmune diseases (30–32) as shown
for CQN. If isolated N-glycans from bLF exert similar effects
as TLR-8 antagonists, they may provide a food-based strategy
for the management of inflammatory disorders and their
intestinal symptoms.
It is unknown whether the N-glycans with different
monosaccharide compositions isolated from bLF have direct
interaction with the receptor ligands or directly with the TLR-8
dimer. Here, we investigated whether the TLR-8 inhibitory
effects of N-glycans, either with or without reduction in mannose
and sialic acid content, are dependent on the agonist used for
stimulation and whether the inhibition is dose dependent. To
this end, HEK293 cells expressing hTLR-8 were pre-exposed for
1 h to different concentrations of either CQN or the N-glycans
and subsequently exposed to agonists ssRNA40 and R848.
We first determined the TLR-8 stimulating capacity of
ssRNA40 and R848 in HEK293 cells expressing hTLR-8. As
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FIGURE 3 | Inhibitory effects of CQN on ssRNA 40 and R848 induced activation of TLR-8. The TLR-8 agonists ssRNA40 (50 µg/mL) and R848 (100 µg/mL) were
used to stimulate TLR-8 expressed in HEK293 cells after pre-incubation with chloroquine (CQN) for 1 h at 0.1, 1, and 10 mg/mL (n = 4). (A) Fold-change activation
induced by CQN compared with the untreated cells/medium. (B) Fold-changes in the inhibition of ssRNA40 or R848 induced TLR-8 activation. NF-κB release was
measured by spectrophotometry at 650 nm. Data is represented as mean ± SEM. Statistical differences were measured using One-way ANOVA and post hoc
Tukey’s test. Significant differences compared to ssRNA40 and R848 are indicated by *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
shown in Figure 3A, ssRNA40-induced TLR-8 activation was
2.3-fold (p < 0.001) higher compared to the medium control
while R848 induced TLR-8 activation 4.5-fold (p < 0.0001). This
activation was differently suppressed by CQN. CQN inhibited
(p < 0.0001) as previously reported, ssRNA40 induced TLR-
8 activation more efficiently than TLR-8 activation by R848.
The inhibition of ssRNA40 induced TLR-8 activation was CQN
dose dependent (40). CQN at concentrations of 0.1, 1, or
10 mg/mL inhibited TLR-8 induced activation 0.7 (p < 0.0001),
0.5 (p < 0.001), and 0.2-fold (p < 0.0001), respectively.
The inhibition of TLR-8 by CQN was less strong when the
agonist used for stimulation was R848. A statistically significant
but mild inhibition occurred at 0.1 mg/mL (p < 0.01) and at
1 mg/mL (p < 0.05) but at a concentration of 10 mg/mL CQN
significantly co-stimulated the R848 induced TLR-8 activation
(p < 0.001) (Figure 3B).
Figure 4 demonstrates the inhibitory capacity of the different
N-glycans from bLF on TLR-8 induced activation by ssRNA40
and R848. The HEK293 cells were incubated with native
N-glycans, N-glycans treated with mannosidase, and N-glycans
treated with sialidase at 1, 2, and 4 mg/mL. No dose-response
relationship was found. The native N-glycans highly reduced
ssRNA40 induced TLR-8 activation by 0.43-fold (p < 0.0001).
This inhibitory effect was already strong at a concentration of
1 mg/mL and was not further increased at the higher dose
(4 mg/mL) Figure 4A. In contrast, when R848 was used to
stimulate the cells, only the high, 4 mg/mL, concentration of
the native N-glycans induced a significant inhibition of the
R848-induced TLR-8 activation and this inhibition was still
minor (Figure 4A).
As shown in Figure 4B, the partially demannosylated
N-glycans inhibited the ssRNA40 induced TLR-8 activation
significantly at all tested concentrations and to a similar extent
as native N-glycans. Although the partially demannosylated
N-glycans slightly reduced the R848 induced TLR-8 activation,
the inhibition was less strong at 4 mg/mL (p < 0.05).
The partially desialylated N-glycans inhibited ssRNA40
induced TLR-8 activation significantly (p < 0.0001) at all tested
concentrations and also to a similar extent as native N-glycans.
For R848 induced TLR-8 activation again a slight inhibition
was observed at an N-glycan concentration of 1 mg/mL which
reached significance at 2 and 4 mg/mL (p < 0.01 and p < 0.001,
respectively) (Figure 4C).
Inhibitory Effects of bLF N-Glycans in
MoDCs
Next, we determined the ability of the N-glycans to modulate
TLR-8 induced activation of human MoDCs. As inhibitory effects
of CQN and of the different isolated N-glycans from bLF were
strong on ssRNA40 induced TLR-8 activation and only minor on
activation induced by R848, we only tested inhibition of ssRNA40
induced TLR-8 activation of MoDCs. We confirmed expression
of TLR-8 in the donor cells (Supplementary Figure S1).
The secretion of IL-6, IL-10, and TNF-α was quantified in
samples after 24 h.
As sensitivity of the HEK293 and MoDCs for ssRNA40
induced TLR-8 was found to be different, we first performed
a dose-response study with ssRNA40 and CQN induced IL-
6 secretion in MoDCs (Supplementary Figure S2). Based on
the results we selected the following concentrations: MoDCs
were incubated for 1 h with 10 µg/mL CQN and 25 µg/mL
of the N-glycans. Afterward, cells were stimulated with
10 µ g/mL ssRNA40.
As shown in Figure 5A, CQN at a concentration of 10 µg/mL
very strongly suppressed ssRNA40 induced IL-6 secretion.
This was less with the N-glycans which were tested at a
higher concentration but the difference in IL-6 secretion was
still significant. The native N-glycans inhibited the ssRNA40
induced IL-6 secretion 0.5-fold (p < 00001). The secretion
of IL-6 was decreased 0.3-fold and 0.4-fold (p < 0.0001),
by the partially demannosylated and desialylated N-glycans,
respectively. Furthermore, the secretion of IL-6 for both
partially demannosylated (p < 0.001) and partially desialylated
(p< 0.01) N-glycans was significantly stronger than that of native
N-glycans.
The secretion of the regulatory cytokine IL-10 was mildly
affected by CQN and unaffected by the native, partially
demannosylated, and partially desialylated N-glycans
(Figure 5B). The ssRNA40 induced TNF-α secretion was
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FIGURE 4 | Impact of the native, partially demannosylated and partially desialylated N-glycans on the inhibition of TLR-8 activation induced with ssRNA40 or R848.
HEK293 cells expressing hTLR-8 were first incubated with (A) native N-glycans, (B) N-glycans treated with mannosidase, and (C) N-glycans treated with sialidase at
4 mg/mL (n = 5). After 1 h, the TLR-8 agonists ssRNA40 (50 µg/mL) and R848 (100 µg/mL) were used to stimulate the cells. NF-κB activation was measured by
spectrophotometry at 650 nm. Data is represented as mean ± SEM. Statistical differences were measured using paired t-test. Significant differences compared to
ssRNA40 and R848 are indicated by *p < 0.05, **p < 0.01, and ****p < 0.0001.
strongly inhibited by CQN but was not reduced by the treatment
with the N-glycans (Figure 5C).
DISCUSSION
In this study, we determined and compared the inhibitory
effects of N-glycans isolated from bLF on the activation of
TLR-8. Also, we assessed its immunomodulatory effects in
human dendritic cells. The impact was compared with a
pharmaceutical agent, i.e., CQN, that is clinically used to
antagonize endosomal TLR activation (27). Previously, we
have reported that dietary N-glycans isolated from bLF are
inhibitors of ssRNA40 induced TLR-8 activation in reporter cell
lines (20). Endosomal activation of TLRs is critical for host
defense. However, excessive stimulation has been linked with the
development of autoimmune disorders. TLR-8 specifically plays
a role in autoimmune disorders because it is involved in the
regulation of TLR-7 and TLR-9 signaling and a direct link has
been found between the dysregulation of TLR-8 activation and
pathological inflammation (25, 41).
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FIGURE 5 | Effect of CQN and isolated native and modified N-glycans on the secretion of IL-6, IL-10, and TNF-α by MoDCs. TLR-8 agonist ssRNA40 (10 µg/mL)
was used to stimulate the cells after pre-incubation with CQN (10 µg/mL) and the native and modified N-glycans at 25 µg/mL. The cytokine secretion of (A) IL-6,
(B) IL-10, and (C) TNF-α is expressed in fold-change compared to ssRNA40 induced secretion of the cytokines. Data is expressed as mean ± SEM. Data represent
4 PBMCs isolations. Statistical differences were measured using One-way ANOVA and post hoc Tukey’s test. Significant differences compared to ssRNA40 are
indicated by **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Toll-like receptor 8 unlike other TLRs exists in inactive
dimeric form before ligand recognition. Its activation is a
multistep process (42). The activation of TLR-8 requires an
acidification step, which occurs in the endosome (43). It
is followed by the binding of the TLR-8 inactive dimer
to ssRNA40 or R848. The dimerization interface of TLR-8
undergoes structural changes that enable ligand recognition,
dimer activation, and downstream signaling (44). Compounds
like CQN, which is a weak base, accumulate in this endosomal
compartment and as a result it suppresses the activation of TLR-8
(45). The N-glycans are small molecules and they are mostly non-
charged. Only the native and partially demannosylated N-glycans
may carry a negative charge due to the presence of sialic acid
but as they did not have a different degree of inhibition as the
native N-glycans it is unlikely that the N-glycans inhibit TLR-8
activation by altering the endosomal acidic environment.
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FIGURE 6 | Chemical structures of antagonists of TLR-8 activation. Images were obtained from the National Center for Biotechnology Information. (A) Three major
N-glycan types are depicted: High mannose type, PubChem Database. CID = 91852027, https://pubchem.ncbi.nlm.nih.gov/compound/91852027; hybrid type,
PubChem Database. CID = 91860397, https://pubchem.ncbi.nlm.nih.gov/compound/91860397; complex type, PubChem Database. CID = 71297682,
https://pubchem.ncbi.nlm.nih.gov/compound/71297682. (B) Chloroquine (CQN), PubChem Database. Chloroquine, CID = 2719, https://pubchem.ncbi.nlm.
nih.gov/compound/Chloroquine. (C) IMO-8400 PubChem Database. Bazlitoran, CID = 119058029, https://pubchem.ncbi.nlm.nih.gov/compound/Bazlitoran.
Endosomal acidification is not the only mechanism of
inhibition identified for antagonists (33). TLR-8 inhibition can
occur by at least two possible other ways. Antagonists can
sequestrate the ligand for TLR-8 or it can hinder the structural
reorganization of the receptor (44). It has been reported that
the inhibitory capacity of CQN depends on the type of TLR
stimuli used (40). As observed in this study, CQN antagonizes
the release of NF-κB when ssRNA40 induced the activation of
TLR-8. CQN at low concentrations had a mild inhibitory effect
and at high concentration manifested a co-stimulatory effect.
In the case of CQN, it has been found that it interacts with
ssRNA40, making it unavailable for binding with TLR-8. There
are no indications that the N-glycans induce inhibition of TLR-8
by binding ssRNA40.
Obstruction of the structural reorganization of the TLR-8
dimer has been shown as an inhibition mechanism by Zhang
et al. (35). The inhibition of R848 induced activation of TLR-
8 occurs at the antagonist binding pocket, where antagonists
bind to prevent conformational changes required for activation
(35). The N-glycans strongly inhibited the ssRNA40 induced
TLR-8 activation, but exerted milder antagonistic effects on
the R848 induced TLR-8 activation. This may suggest that the
antagonistic effect of N-glycans is due to the direct interaction
of the N-glycans with the TLR-8 dimer.
The inhibitory capacity of the N-glycans may be linked to
their structural characteristics. While TLR-8 recognizes nucleic
acid sequences and structures containing tricyclic heterocycles,
most endosomal TLRs antagonists, such as CQN, contain phenyl
substituted bicyclic heterocyclic rings (33). Recently a new
class of compounds called immune modulatory oligonucleotides
(IMO), have shown inhibitory activity on endosomal TLRs (46).
A structural similarity between the IMO compounds and the
N-glycans is that they carry oxygen-based heterocyclic rings.
While the nucleotides in the IMO consists of complex oligomers
of pentoses linked to a heterocyclic base and a phosphate
group, the N-glycans consist of units of hexoses linked by
glycosidic bonds (Figure 6). Although N-glycans differ from
oligonucleotide structures, X-ray crystal structure studies have
shown that hydrogen bond interactions are important for the
interaction between antagonists and the TLR-8 dimer (47).
While CQN appears to bind to ssRNA40 and R848 ligands, the
N-glycans seem to interact directly with the TLR-8 receptor.
Frontiers in Immunology | www.frontiersin.org 9 May 2020 | Volume 11 | Article 790
fimmu-11-00790 May 10, 2020 Time: 19:18 # 10
Figueroa-Lozano et al. Dietary N-Glycans From Bovine Lactoferrin
The different ways by which CQN and N-glycans inhibit
TLR-8 activation should also explain the difference in efficacy
to attenuate TLR-8 induced activation of human MoDCs. CQN
inhibits the production of IL-6, IL-10, and TNF-α in MoDCs.
This strong impact of CQN probably is due to a complete binding
and neutralization of ssRNA40. In contrast, the N-glycans only
inhibited the secretion of IL-6 and did not reduce the secretion
of IL-10 and TNF-α. Although the various N-glycans tested
did not differently inhibit the ssRNA40 induced activation on
TLR-8 expressing reporter cells, the partially demannosylated,
and partially desialylated N-glycans had a stronger inhibitory
effect on IL-6 secretion in MoDCs. This should be explained
by the fact that MoDCs are carrying more pattern recognition
receptors than TLR8. In previous studies it has been shown that
the activation pattern of bLF on other TLRs is dependent on
the sialylation and mannosylation composition of the N-glycans
(20). This may explain the stronger impact of the partially
demannosylated and partially desialylated N-glycans on IL-6
secretion in MoDCs which probably involve other receptors that
sense glycans, such as C-type lectines (48).
This study was undertaken in our efforts to identify food
components that can be used in anti-inflammatory diets.
Targeting the inhibition of IL-6 by bLF has positive clinical
implications, for instance for patients with rheumatoid arthritis
that fail anti-TNF therapy (49). However, other diseases may
benefit from this approach as well, such as Crohn’s disease,
systemic lupus erythematosus, systemic sclerosis, and some
cancers (50). The potential anti-inflammatory effects derived
from a dietary component such as the N-glycans from bLF
can have a great impact when used for therapeutic purposes.
Compared to CQN, which can induce severe adverse reactions,
such as retinopathy, psychiatric, cardiac, and neuromuscular
adverse effects (30), bLF and its derivates, peptides and N-glycans,
have no adverse effects (51, 52). Additionally, as shown in this
study, N-glycans are selective inhibitors of TLR-8 activation
whereas CQN is not and this treat is considered a challenge in
the therapy of rheumatoid arthritis with antimalarials (53, 54).
The prevention of adverse reactions while reducing or controlling
inflammation is relevant for the long term use of a therapeutical
treatment and the well-being of any patient.
CONCLUSION
We show that N-glycans isolated from bLF are able to inhibit
specifically TLR-8 and that this impacts the production of IL-6
in MoDCs. Our findings indicate that this impact is higher in
MoDCs with partially demannosylated and partially desialylated
N-glycans. Our findings demonstrate that the N-glycans are as
effective as CQN in reducing production of IL-6. As TLR-8 over
activation is involved in many inflammatory disorders, our data
suggest that lactoferrin may fit into an anti-inflammatory diet.
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